To evaluate compliance and patients' satisfaction in mono and combination treatment of Candesartan cilexetil (Atacand)/ Candesartan cilexetil 16mg, hydrochlorothiazide 12.5mg (Atacand plus) in hypertension.
Study Type
OBSERVATIONAL
Enrollment
9,000
Research Site
Seoul, Jongro-gu, South Korea
Research Site
Seoul, Kangnam-gu, South Korea
Research Site
Seoul, Songpa-gu, South Korea
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.